The androgen receptor (AR) plays a role in the pathogenesis of prostate cancer and can be expressed in invasive breast cancer (Itkonen and Mills 2012; Gonzalez et al 2008). AR is the product of the AR gene, which is located on the X chromosome. AR is in the nuclear receptor superfamily and is part of the steroid receptor family, and it has a six-region structure with a defined functional domain (Itkonen and Mills 2012).

Amplification of the AR gene and AR mutations occur in 30% and 1-30% of castration-resistant prostate cancer, respectively (Waltering et al. 2012). AR expression is measured using immunohistochemistry (IHC), and is detectable in the majority of castration-resistant prostate cancer (Linja et al. 2001; Waltering et al. 2012) and 75% of invasive breast cancers (Collins et al. 2011; Gonzalez et al 2008).

Related Pathways

Contributors: Justin M. Balko, Pharm. D., Ph.D., Ingrid A. Mayer, M.D., M.S.C.I., Mia Levy, M.D., Ph.D., Carlos L. Arteaga, M.D.

Suggested Citation: Balko, J.M., Mayer, I.A., Levy, M., Arteaga, C.L. 2016. AR. My Cancer Genome (Updated September 2016)

Modified: September 12, 2016

Disclaimer: The information presented at is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.